Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Balinatunfib · SAR-441566

Small molecule · developed by Sanofi

Phase 2 Most advanced trial (none active)
SNY Developer

What is Balinatunfib?

Balinatunfib (SAR441566) is an oral tablet formulation. It is being studied in ulcerative colitis and Crohn's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-441566
Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
PLY98MAN4C

Conditions studied

Colitis UlcerativeCrohn's Disease

More from Sanofi

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Balinatunfib

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.